■在医疗保健环境中,中心静脉导管相关血流感染(CVC-BSIs)是一个严重的问题,因为它们会增加发病率。死亡率,和医疗费用率。抗生素耐药性的发展使这些疾病的管理更具挑战性。纳米技术最近作为产生新的抗微生物剂的可行方法引起了人们的兴趣。通过将抗菌纳米材料放在导管上,这可能会通过阻止细菌粘附和生长来减少生病的可能性。抗菌添加剂可以逐渐释放完成,随着时间的推移,通过生物工程部门进行保护。为了预防和治疗CVC-BSIs,这项研究将评估基于纳米颗粒的抗菌药物的疗效。
■在网络荟萃分析(MA)和系统评价(SR)中,我们使用Cochrane中央对照试验注册中心(CENTRAL)寻找2010年1月至2021年9月发表的研究,EMBASE,MEDLINE,CINAHL,和WebofScience数据库。在使用纳入和排除标准筛选出版物后,共有10篇论文被纳入审查。
■与传统导管相比,抗菌导管(AC)的实施和氯己定(CHG)或磺胺嘧啶银(SS)的使用表明,通过生物工程部门,每1000个导管日(CD)中中心静脉导管相关血流感染(CVC-BSIs)的发生率显著降低(比率os(ORs)和95%可信间隔(CrIs)分别为0.66和0.54)。此外,这些干预措施与最低的导管定植率(CC)有关,OR和95%的CrIs分别为0.45和0.31,强调其作为将导管使用相关的感染风险降至最低以及生物工程部门创新的有效策略的潜力。
■因此,CVC-BSI在使用基于纳米颗粒的抗微生物药物进行预防和治疗方面显示出巨大的希望。由于其特殊的特点和作用方式,他们是提高临床使用中心静脉导管的安全性和有效性的有力候选人.由于这方面的研究和发展,基于纳米颗粒的涂层和疗法可用于减轻CVC-BSI的影响并增强患者的预后。
UNASSIGNED: In healthcare settings, Central Venous Catheter-Associated Bloodstream Infections (CVC-BSIs) present a serious problem since they raise morbidity, mortality, and medical expense rates. The management of these illnesses is made more challenging by the development of antimicrobiotic resistance. Nanotechnology has attracted interest recently as a viable method for creating new antimicrobial agents. By putting antibacterial nanomaterials onto the catheter\'s appear, that may reduce the likelihood of getting sick by stopping germs from adhering and growing. Antimicrobial additives can be released gradually finishes, protecting over time through bioengineering sectors. To prevent and treat CVC-BSIs, this study will assess the efficacy of antimicrobial medicines based on nanoparticles.
UNASSIGNED: In the network Meta-Analyses (MA) and Systematic Review (SR), we looked for studies published from January 2010 to September 2021 using the Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, MEDLINE, CINAHL, and Web of Science databases. Ten papers in all were included in the review following the screening of the publications using inclusion and exclusion criteria.
UNASSIGNED: In contrast to conventional catheters, the implementation of Antimicrobial Catheters (AC) and the use of chlorhexidine (CHG) or Silver Sulfadiazine (SS) demonstrated notably reduced occurrences of Central Venous Catheter-Associated Bloodstream Infections (CVC-BSIs) per 1000 Catheter Days (CD) (with Odds Ratios (ORs) and 95% Credibility Intervals (CrIs) of 0.66 and 0.54, respectively) by bioengineering sectors. Moreover, these interventions were linked to the lowest rate of Catheter Colonization (CC), with ORs as well as 95% CrIs of 0.45 and 0.31, respectively, underscoring their potential as effective strategies for minimizing the risk of infections associated with catheter use as well as bioengineering sectors innovations.
UNASSIGNED: As a result, CVC-BSI has shown significant promise for prevention and treatment with nanoparticle-based antimicrobial medicines. Due to their special characteristics and modes of action, they are strong candidates for improving the security and effectiveness of central venous catheter use in clinical settings. Due to ongoing research and development in this area, nanoparticle-based coatings and therapies may be used to lessen the impact of CVC-BSIs and enhance patient outcomes.